Moreover, clinical evidence indicate that the patients using anxiolytic Lorazepam, which has off-target agonism of GPR68, had a 3.8-fold higher rate of recurrent pancreatic cancer compared to control group [23, 24]. Here, GPR68 is linked to pancreatic neoplasm.